These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10567309)

  • 1. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients.
    John R; Lietz K; Burke E; Ankersmit J; Mancini D; Suciu-Foca N; Edwards N; Rose E; Oz M; Itescu S
    Circulation; 1999 Nov; 100(19 Suppl):II229-35. PubMed ID: 10567309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic sensitization in recipients of left ventricular assist devices.
    John R; Lietz K; Schuster M; Naka Y; Rao V; Mancini DM; Rose EA; Smith CR; Oz MC; Edwards NM; Itescu S
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):578-91. PubMed ID: 12658200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
    Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
    Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications.
    Itescu S; John R
    Ann Thorac Surg; 2003 Jun; 75(6 Suppl):S58-65. PubMed ID: 12820736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.
    Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N
    Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.
    Nair V; Sawinski D; Akalin E; Friedlander R; Ebcioglu Z; Sehgal V; Dinavahi R; Khaim R; Ames S; Lerner S; Murphy B; Bromberg JS; Heeger PS; Schröppel B
    Clin Transplant; 2012; 26(3):E261-8. PubMed ID: 22686949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
    J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates.
    Sivasai KS; Mohanakumar T; Phelan D; Martin S; Anstey ME; Brennan DC
    Clin Exp Immunol; 2000 Mar; 119(3):559-65. PubMed ID: 10691931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of allosensitized cardiac transplant candidates.
    Velez M; Johnson MR
    Transplant Rev (Orlando); 2009 Oct; 23(4):235-47. PubMed ID: 19778695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.